DOCSLIB.ORG

NASDAQ-100® 2X Strategy Fund SCHEDULE of INVESTMENTS (Unaudited) March 31, 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NASDAQ-100® 2X Strategy Fund SCHEDULE of INVESTMENTS (Unaudited) March 31, 2021 NASDAQ-100® 2x Strategy Fund SCHEDULE OF INVESTMENTS (Unaudited) March 31, 2021 Shares Value COMMON STOCKS† - 58.1% Technology - 25.7% Apple, Inc. 54,179 $ 6,617,965 Microsoft Corp. 24,341 5,738,878 NVIDIA Corp. 3,045 1,625,817 Intel Corp. 19,953 1,276,992 Adobe, Inc.* 2,351 1,117,595 Broadcom, Inc. 2,005 929,638 Texas Instruments, Inc. 4,519 854,046 QUALCOMM, Inc. 5,579 739,720 Applied Materials, Inc. 4,507 602,135 Intuit, Inc. 1,345 515,216 Micron Technology, Inc.* 5,494 484,626 Advanced Micro Devices, Inc.* 5,949 466,996 Lam Research Corp. 702 417,858 Fiserv, Inc.* 3,288 391,404 Activision Blizzard, Inc. 3,805 353,865 Zoom Video Communications, Inc. — Class A* 1,001 321,611 Autodesk, Inc.* 1,081 299,599 Analog Devices, Inc. 1,812 281,005 NXP Semiconductor N.V. 1,360 273,822 KLA Corp. 757 250,113 ASML Holding N.V. — Class G 382 235,832 Workday, Inc. — Class A* 884 219,612 Microchip Technology, Inc. 1,322 205,201 Cognizant Technology Solutions Corp. — Class A 2,606 203,581 Electronic Arts, Inc. 1,413 191,278 Cadence Design Systems, Inc.* 1,370 187,676 DocuSign, Inc.* 916 185,444 Synopsys, Inc.* 748 185,339 Paychex, Inc. 1,771 173,593 Marvell Technology Group Ltd. 3,299 161,585 NetEase, Inc. ADR 1,471 151,896 Xilinx, Inc. 1,205 149,299 Skyworks Solutions, Inc. 810 148,619 ANSYS, Inc.* 426 144,653 Atlassian Corporation plc — Class A* 653 137,626 Maxim Integrated Products, Inc. 1,316 120,243 Cerner Corp. 1,504 108,108 Splunk, Inc.* 794 107,571 Check Point Software Technologies Ltd.* 689 77,147 Total Technology 26,653,204 Communications - 18.3% Amazon.com, Inc.* 1,625 5,027,880 Facebook, Inc. — Class A* 7,763 2,286,436 Alphabet, Inc. — Class C* 1,057 2,186,542 Alphabet, Inc. — Class A* 971 2,002,707 Comcast Corp. — Class A 22,449 1,214,715 Netflix, Inc.* 2,175 1,134,611 Cisco Systems, Inc. 20,733 1,072,103 T-Mobile US, Inc.* 6,103 764,645 Charter Communications, Inc. — Class A* 951 586,786 Booking Holdings, Inc.* 201 468,298 MercadoLibre, Inc.* 245 360,674 JD.com, Inc. ADR* 4,080 344,066 Baidu, Inc. ADR* 1,333 289,994 Pinduoduo, Inc. ADR* 1,697 227,194 eBay, Inc. 3,342 204,664 Match Group, Inc.* 1,321 181,479 Okta, Inc.* 595 131,156 Sirius XM Holdings, Inc.1 20,331 123,816 CDW Corp. 692 114,699 VeriSign, Inc.* 555 110,312 Trip.com Group Ltd. ADR* 2,587 102,523 Fox Corp. — Class A 1,642 59,293 Fox Corp. — Class B 1,258 43,942 Total Communications 19,038,535 Consumer, Non-cyclical - 7.7% PayPal Holdings, Inc.* 5,752 1,396,816 PepsiCo, Inc. 6,775 958,324 Amgen, Inc. 2,836 705,625 Intuitive Surgical, Inc.* 578 427,108 Mondelez International, Inc. — Class A 6,935 405,906 Gilead Sciences, Inc. 6,171 398,832 Automatic Data Processing, Inc. 2,102 396,164 Illumina, Inc.* 717 275,371 Vertex Pharmaceuticals, Inc.* 1,277 274,414 Moderna, Inc.* 1,963 257,055 Regeneron Pharmaceuticals, Inc.* 517 244,613 Kraft Heinz Co. 6,007 240,280 Keurig Dr Pepper, Inc. 6,911 237,531 Monster Beverage Corp.* 2,593 236,196 Align Technology, Inc.* 389 210,655 Biogen, Inc.* 748 209,253 IDEXX Laboratories, Inc.* 420 205,510 Cintas Corp. 517 176,457 DexCom, Inc.* 472 169,632 Alexion Pharmaceuticals, Inc.* 1,080 165,143 Verisk Analytics, Inc. — Class A 799 141,175 Seagen, Inc.* 890 123,585 Incyte Corp.* 1,080 87,772 Total Consumer, Non-cyclical 7,943,417 Consumer, Cyclical - 5.5% Tesla, Inc.* 3,833 2,560,176 Costco Wholesale Corp. 2,175 766,644 Starbucks Corp. 5,782 631,799 Marriott International, Inc. — Class A* 1,593 235,939 Walgreens Boots Alliance, Inc. 4,243 232,941 Ross Stores, Inc. 1,751 209,963 Lululemon Athletica, Inc.* 614 188,320 O'Reilly Automotive, Inc.* 345 175,001 PACCAR, Inc. 1,704 158,335 Peloton Interactive, Inc. — Class A* 1,295 145,610 Fastenal Co. 2,821 141,840 Dollar Tree, Inc.* 1,155 132,201 Copart, Inc.* 1,161 126,096 Total Consumer, Cyclical 5,704,865 Utilities - 0.6% Exelon Corp. 4,795 209,733 American Electric Power Company, Inc. 2,439 206,583 Xcel Energy, Inc. 2,640 175,586 Total Utilities 591,902 NASDAQ-100® 2x Strategy Fund SCHEDULE OF INVESTMENTS (Unaudited) March 31, 2021 Shares Value COMMON STOCKS† - 58.1% (continued) Industrial - 0.3% CSX Corp. 3,745 $ 361,093 Total Common Stocks (Cost $43,915,641) 60,293,016 MUTUAL FUNDS† - 24.1% Guggenheim Strategy Fund II2 770,056 19,235,987 Guggenheim Ultra Short Duration Fund — Institutional Class2 575,746 5,734,427 Total Mutual Funds (Cost $24,658,017) 24,970,414 Face Amount U.S. TREASURY BILLS†† - 24.1% U.S. Treasury Bills 0.09% due 04/01/213,4 $ 7,100,000 7,100,000 0.03% due 04/01/213,4 5,687,000 5,687,000 0.04% due 04/01/213,4 3,000,000 3,000,000 0.01% due 04/22/214,5 1,158,000 1,157,992 U.S. Cash Management Bill 0.03% due 08/03/214 8,000,000 7,999,207 Total U.S. Treasury Bills (Cost $24,944,197) 24,944,199 REPURCHASE AGREEMENTS††,6 - 10.9% J.P. Morgan Securities LLC issued 03/31/21 at 0.01% due 04/01/213 6,060,363 6,060,363 Barclays Capital, Inc. issued 03/31/21 at 0.01% due 04/01/213 2,755,335 2,755,335 BofA Securities, Inc. issued 03/31/21 at 0.01% due 04/01/213 2,514,673 2,514,673 Total Repurchase Agreements (Cost $11,330,371) 11,330,371 Shares SECURITIES LENDING COLLATERAL†,7 - 0.1% Money Market Fund First American Government Obligations Fund — Class Z, 0.03%8 95,300 95,300 Total Securities Lending Collateral (Cost $95,300) 95,300 Total Investments - 117.3% (Cost $104,943,526) $ 121,633,300 Other Assets & Liabilities, net - (17.3)% (17,920,610) Total Net Assets - 100.0% $ 103,712,690 Futures Contracts Value and Number of Unrealized Description Contracts Expiration Date Notional Amount Appreciation** Equity Futures Contracts Purchased† NASDAQ-100 Index Mini Futures Contracts 76 Jun 2021 $ 19,888,820 $ 231,850 Total Return Swap Agreements Value and Unrealized Payment Appreciation Counterparty Index Financing Rate Pay Frequency Maturity Date Units Notional Amount (Depreciation) OTC Equity Index Swap Agreements†† Goldman Sachs International NASDAQ-100 Index 0.64% (1 Week USD LIBOR + 0.55%) At Maturity 04/08/21 3,210 $ 42,020,104 $ 190,144 BNP Paribas NASDAQ-100 Index 0.76% (1 Month USD LIBOR + 0.65%) At Maturity 04/08/21 381 4,994,079 (232,042) Barclays Bank plc NASDAQ-100 Index 0.59% (1 Week USD LIBOR + 0.50%) At Maturity 04/07/21 6,134 80,301,707 (4,172,341) $ 127,315,890 $ (4,214,239) * Non-income producing security. ** Includes cumulative appreciation (depreciation). † Value determined based on Level 1 inputs. †† Value determined based on Level 2 inputs. 1 All or a portion of this security is on loan at March 31, 2021. 2 Affiliated issuer. 3 All or a portion of this security is pledged as equity index swap collateral at March 31, 2021. 4 Rate indicated is the effective yield at the time of purchase. 5 All or a portion of this security is pledged as futures collateral at March 31, 2021. 6 Repurchase Agreements. 7 Securities lending collateral. 8 Rate indicated is the 7-day yield as of March 31, 2021. ADR — American Depositary Receipt LIBOR — London Interbank Offered Rate plc — Public Limited Company .
Load more

Recommended publications
  • Amgen and Incyte – the Biotechnology Acquisition
    Amgen and Incyte – the biotechnology acquisition Ana Carolina Coelho Student number: 152416013 Dissertation written under the supervision of António Luís Borges de Assunção Dissertation submitted in partial fulfilment of requirements for the MSc in Finance, at the Universidade Católica Portuguesa, May 2018 Abstract The main goal of this dissertation is to study the hypothesis of an acquisition in the biotechnology industry, between Amgen (acquirer) and Incyte (target). Amgen is a U.S.-based biotechnology company currently facing a decrease in sales, mainly due to an increase in the market share of generic drugs and the rise of biosimilar products. To offset the poor performance, it is looking for an acquisition in its industry, for which Incyte could be a suitable target. Incyte belongs to the U.S.-biotechnology industry, and although it has a shy presence in the market with only two released drugs, its revenues are expected to increase significantly in the near future. The combination of these companies would allow knowledge transfer about research and development process of new drugs, a stronger position in Europe, and a higher investment power to apply in R&D. The combined company would be able to decrease the number of employees due to duplication of jobs and decrease the cost of sales, as the power over suppliers increases. The potential synergies are valued at $28,522.8 million, of which $16,739.2 million are more likely to be realized. The combined firm, after the introduction of synergies, is expected to generate the same or even higher returns than the sum of the stand- alone businesses and higher growth rates, fulfilling Amgen’s need of growth.
    [Show full text]
  • Match Group, Inc. (Exact Name of Registrant As Specified in Its Charter)
    As filed with the Securities and Exchange Commission on August 8, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from__________to__________ Commission File No. 001-37636 Match Group, Inc. (Exact name of registrant as specified in its charter) Delaware 26-4278917 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 8750 North Central Expressway, Suite 1400 , Dallas , Texas 75231 (Address of registrant’s principal executive offices) ( 214 ) 576-9352 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of exchange on which registered Common Stock, par value $0.001 MTCH The Nasdaq Stock Market LLC (Nasdaq Global Select Market) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
    [Show full text]
  • (SB #097802) [email protected]
    Electronically FILED by Superior Court of California, County of Los Angeles on 12/04/2020 09:16 AM Sherri R. Carter, Executive Officer/Clerk of Court, by M. Mariscal,Deputy Clerk 20SMCV01866 Assigned for all purposes to: Santa Monica Courthouse, Judicial Officer: H. Ford III 1 DANIEL M. PETROCELLI (S.B. #097802) [email protected] 2 MOLLY M. LENS (S.B. #283867) [email protected] 3 O’MELVENY & MYERS LLP 1999 Avenue of the Stars, 8th Floor 4 Los Angeles, CA 90067-6035 Telephone: (310) 553-6700 5 Facsimile: (310) 246-6779 6 ERIC AMDURSKY (S.B. #180288) [email protected] 7 O'MELVENY & MYERS LLP 2765 Sand Hill Road 8 Menlo Park, California 94025 Telephone: (650) 473-2600 9 Facsimile: (650) 473-2601 10 Attorneys for Plaintiff ACTIVISION BLIZZARD, INC. 11 12 SUPERIOR COURT OF THE STATE OF CALIFORNIA 13 COUNTY OF LOS ANGELES, WEST DISTRICT 14 ACTIVISION BLIZZARD, INC., a Delaware Case No. Corporation, 15 Plaintiff, COMPLAINT FOR: 16 vs. (1) Intentional Interference with 17 Contract; NETFLIX, INC., a Delaware Corporation, and 18 DOES 1 through 25, inclusive, (2) Unfair Competition – Cal. Bus. & Prof. Code §§ Code 17200 et seq.; and 19 Defendants. (3) Aiding and Abetting Breach of 20 Fiduciary Duty 21 DEMAND FOR JURY TRIAL 22 23 24 25 26 27 28 COMPLAINT 1 Plaintiff Activision Blizzard, Inc. (“Plaintiff” or “Activision”), for its complaint against 2 Netflix, Inc. (“Netflix” or “Defendant”), alleges on knowledge as to itself and its own acts, and on 3 information and belief as to all other matters, as follows: 4 NATURE OF ACTION 5 1.
    [Show full text]
  • Activision Blizzard, Inc
    Investment Club Presentation Activision Blizzard, Inc. (ATVI) Analyst: Niko Martinovic 5-Yr Stock Performance $90 $80 $70 $60 $50 $40 $30 Decline in stock primarily driven by analyst sentiment changes, missing expectations, CFO firings, $20 and most recently, Bungie games leaving ATVI $10 $0 1/15/20144/15/20147/15/201410/15/20141/15/20154/15/20157/15/201510/15/20151/15/20164/15/20167/15/201610/15/20161/15/20174/15/20177/15/201710/15/20171/15/20184/15/20187/15/201810/15/2018 Source: AIM/Martinovic 2018, Company Filings, S&P Capital IQ, and IBIS World 2 They’re Wrong Activision Blizzard has three meaningful and diverse revenue streams that can all grow in unique ways. E-Sports and Virtual Reality are the most exciting growth opportunities in this industry and ATVI is the best positioned to take advantage of it with the power of their brands, aggressive R&D spend, and patience. Source: 3 Note: Three Year Stock Performance ATVI has outperformed the S&P consistently since early 2017 while the Peer Set1 has reverted back. 160.00% 140.00% Stock Price $46.85 Shares Outstanding $762.41mm 120.00% Market Cap $36.08bn 52 Week Range $43.71-$84.68 100.00% Avg. Volume 7,550,000 EPS (TTM) $2.13 80.00% Past Month Performance -1.60% Past 1 Year -33.63% 60.00% Past 5 Year 170.36% 40.00% 20.00% 0.00% -20.00% -40.00% 1/15/2016 4/15/2016 7/15/2016 10/15/2016 1/15/2017 4/15/2017 7/15/2017 10/15/2017 1/15/2018 4/15/2018 7/15/2018 10/15/2018 S&P ATVI Peer Set Source: AIM/Martinovic 2018, Company Filings, S&P Capital IQ, and IBIS World 4 1Electronic Arts, Ubisoft, Take Two Interactive, Square Enix, and Zynga Company Overview & Monetization Activision Blizzard, Inc.
    [Show full text]
  • Keurig to Acquire Dr Pepper Snapple for $18.7Bn in Cash
    Find our latest analyses and trade ideas on bsic.it Coffee and Soda: Keurig to acquire Dr Pepper Snapple for $18.7bn in cash Dr Pepper Snapple Group (NYSE:DPS) – market cap as of 17/02/2018: $28.78bn Introduction On January 29, 2018, Keurig Green Mountain, the coffee group owned by JAB Holding, announced the acquisition of soda maker Dr Pepper Snapple Group. Under the terms of the reverse takeover, Keurig will pay $103.75 per share in a special cash dividend to Dr Pepper shareholders, who will also retain 13 percent of the combined company. The deal will pay $18.7bn in cash to shareholders in total and create a massive beverage distribution network in the U.S. About Dr Pepper Snapple Group Incorporated in 2007 and headquartered in Plano (Texas), Dr Pepper Snapple Group, Inc. manufactures and distributes non-alcoholic beverages in the United States, Mexico and the Caribbean, and Canada. The company operates through three segments: Beverage Concentrates, Packaged Beverages, and Latin America Beverages. It offers flavored carbonated soft drinks (CSDs) and non-carbonated beverages (NCBs), including ready-to-drink teas, juices, juice drinks, mineral and coconut water, and mixers, as well as manufactures and sells Mott's apple sauces. The company sells its flavored CSD products primarily under the Dr Pepper, Canada Dry, Peñafiel, Squirt, 7UP, Crush, A&W, Sunkist soda, Schweppes, RC Cola, Big Red, Vernors, Venom, IBC, Diet Rite, and Sun Drop; and NCB products primarily under the Snapple, Hawaiian Punch, Mott's, FIJI, Clamato, Bai, Yoo- Hoo, Deja Blue, ReaLemon, AriZona tea, Vita Coco, BODYARMOR, Mr & Mrs T mixers, Nantucket Nectars, Garden Cocktail, Mistic, and Rose's brand names.
    [Show full text]
  • Check Point Firewall V1.0
    Check Point Firewall Benchmark v1.0 Editor: John Traenkenschuh December 2007 Copyright 2001-2007, The Center for Internet Security (CIS) http://cisecurity.org [email protected] TERMS OF USE AGREEMENT Background. The Center for Internet Security ("CIS") provides benchmarks, scoring tools, software, data, information, suggestions, ideas, and other services and materials from the CIS website or elsewhere (―Products‖) as a public service to Internet users worldwide. Recommendations contained in the Products (―Recommendations‖) result from a consensus-building process that involves many security experts and are generally generic in nature. The Recommendations are intended to provide helpful information to organizations attempting to evaluate or improve the security of their networks, systems, and devices. Proper use of the Recommendations requires careful analysis and adaptation to specific user requirements. The Recommendations are not in any way intended to be a ―quick fix‖ for anyone‘s information security needs. No Representations, Warranties, or Covenants. CIS makes no representations, warranties, or covenants whatsoever as to (i) the positive or negative effect of the Products or the Recommendations on the operation or the security of any particular network, computer system, network device, software, hardware, or any component of any of the foregoing or (ii) the accuracy, reliability, timeliness, or completeness of the Products or the Recommendations. CIS is providing the Products and the Recommendations ―as is‖ and ―as available‖ without representations, warranties, or covenants of any kind. User Agreements. By using the Products and/or the Recommendations, I and/or my organization (―We‖) agree and acknowledge that: 1. No network, system, device, hardware, software, or component can be made fully secure; 2.
    [Show full text]
  • Align Technology, Inc. 2006 Annual Report
    our path is clear... Align Technology, Inc. Inc. Technology, Align 2006 Annual Report2006 Annual 881 Martin Ave. Santa Clara, CA 95050 408.470.1000 www.aligntech.com Align Technology, Inc. 002CS-13275 2006 Annual Report in every sense officers and directors EXECUTIVE TEAM Len Hedge Joseph S. Lacob Thomas M. Prescott Vice President, Operations Partner Kleiner Perkins Caufield & Byers President and Michael Henry Chief Executive Officer Vice President, C. Raymond Larkin, Jr. Eldon M. Bullington Information Technology Chairman of the Board Vice President, Finance and Chief Information Officer Align Technology, Inc. and Chief Financial Officer Gil Laks George Morrow Hossein Arjomand Vice President, International Executive Vice President Amgen, Inc. Vice President, Research Darrell Zoromski and Development Vice President, Global Marketing Thomas M. Prescott Sonia Clark and Chief Marketing Officer President and Chief Executive Officer Vice President, Human Resources BOARD OF DIRECTORS Align Technology, Inc. Dan S. Ellis H. Kent Bowen Vice President, Bruce Rauner Professor of Greg J. Santora North American Sales Business Administration Former Chief Financial Officer Harvard University Graduate Shopping.com Roger E. George School of Business Administration Vice President, Legal and Warren S. Thaler Corporate Affairs, General Counsel David E. Collins President and Corporate Secretary Former Vice Chairman Gund Investment Corporation Johnson & Johnson shareholder information CORPORATE INVESTOR RELATIONS TRANSFER AgENT HEADQUARTERS For additional
    [Show full text]
  • FEA Newsletter October 2011
    October Issue - 11th Anniversary Issue PreSys™ R3 Release BETA CAE Systems S.A. FE Modeling Tool release ANSA v13.2.0 ESI engineer David Prono transatlantic boat race The Stealth LLNL M. King (left) and physicist W. Moss B-2 Spirit compression test helmet pad TABLE OF CONTENTS 2. Table of Contents 4. FEA Information Inc. Announcements 5. Participant & Industry Announcements 6. Participants 7. BETA CAE Systems S.A. announces the release of ANSA v13.2.0 11. Making A Difference Guenter & Margareta Mueller 13. LLNL researchers find way to mitigate traumatic brain injury 16. ESI sponsors in-house engineer David Prono for a transatlantic boat race 18. ETA - PreSys™ R3 Release FE Modeling Tool Now Offers ‘Part Groups’ Function 20. Toyota Collaborative Safety Research Center 23. LSTC SID-IIs-D FAST - Finite Element Model 27. Website Showcase The Snelson Atom 28. New Technology - “Where You At?” 29. SGI - Benchmarks- Top Crunch.org 35. Aerospace - The Stealth 2 36. Reference Library - Available Books 38. Solutions - PrePost Processing - Model Editing 39. Solutions - Software 40. Cloud Services – SGI 42. Cloud Services – Gridcore 43. Global Training Courses 50. FEA - CAE Consulting/Consultants 53. Software Distributors 57. Industry News - MSC.Software 59. Industry News – SGI 60. Industry News - CRAY 3 FEA Information Inc. Announcements Welcome to our 11th Anniversary Issue. A special thanks to a few of our first participant’s that supported, and continue to support FEA Information Inc.: Abe Keisoglou and Cathie Walton, (ETA) US, Brian Walker, Oasys, UK Christian Tanasecu, SGI, Guenter and Margareta Mueller, CADFEM Germany, Sam Saltiel, BETA CAE Systems SA, Greece Companies - JSOL - LSTC With this issue we will be adding new directions, opening participation, and have brought on additional staff.
    [Show full text]
  • 2021 Honored Companies Please Join Us As We Give Special Recognition and Honor S&P 500 and F1000 Companies with at Least 35% of Board Seats Held by Women
    Cipriani 42nd St | November 10, 2021 | 7:30 AM-11:00 AM 2021 Honored Companies Please join us as we give special recognition and honor S&P 500 and F1000 companies with at least 35% of board seats held by women. 50% + AMN Healthcare General Motors Co. Sally Beauty Holdings, Inc. Autodesk, Inc. Hasbro, Inc. Schnitzer Steel Industries, Inc. Bed, Bath & Beyond, Inc. Hawaiian Electric Industries, Inc. Science Applications International Corporation (SAIC) Best Buy Companies Inc. Healthpeak Properties, Inc. Steelcase Inc. Big Lots Inc. Herman Miller, Inc. Summit Materials, Inc. Bright Horizons Family Solutions, Inc. HNI Corporation Tapestry, Inc. Caleres, Inc. J.Crew Group, Inc. Thrivent Financial Casey’s General Stores, Inc. L Brands, Inc. TIAA Celanese Corporation Micron Technology Inc Tiffany & Co. Chico’s Fas, Inc. Navient Corporation ULTA Beauty Inc. Citi Omnicom Group Inc. ViacomCBS Inc. Coty Inc. PC Connection, Inc. Welltower Inc. DaVita Pitney Bowes, Inc. Western Digital Corporation EQT Corporation The Procter & Gamble Co. Williams-Sonoma, Inc. Etsy, Inc. The Progressive Corporation 40% + Abercrombie & Fitch Co. Genworth Financial The ODP Corporation ABM Industries, Inc. Globe Life Inc. Penn Mutual Accenture The Goldman Sachs Group, Inc. Phillips 66 Company AES Corporation Groupon Inc. Principal Financial Group Inc. Afliated Managers Group (AMG) H & R Block, Inc. PROG Holdings, Inc. AGNC Investment Corp. The Hershey Companies Quest Diagnostics Inc. Alliant Energy Hewlett Packard Enterprise RR Donnelley & Sons Co. Amazon.com, Inc. Hill-Rom Holdings Inc. Reinsurance Group Of America, Inc. American Water Works, Inc. Hilton Worldwide Holdings, Inc. Reliance Steel and Aluminum Co. Amica Mutual Insurance Company HP Inc.
    [Show full text]
  • Fund Holdings As of 6/30/2021 Massmutual Balanced Fund Invesco Prior to 5/1/2021, the Fund Name Was Massmutual Premier Balanced Fund
    Fund Holdings As of 6/30/2021 MassMutual Balanced Fund Invesco Prior to 5/1/2021, the Fund name was MassMutual Premier Balanced Fund. Fund Shares or Par Position Market Security Name Ticker CUSIP Weighting % Amount Value Apple Inc AAPL 037833100 3.91 48,433 6,633,384 Microsoft Corp MSFT 594918104 3.45 21,552 5,838,437 USTREAS T-Bill Auction Ave 3 Mon 1.69 2,862,977 JPMorgan Chase & Co JPM 46625H100 1.56 16,948 2,636,092 Verizon Communications Inc VZ 92343V104 1.45 43,768 2,452,321 The Home Depot Inc HD 437076102 1.42 7,556 2,409,533 Intel Corp INTC 458140100 1.29 38,961 2,187,271 Procter & Gamble Co PG 742718109 1.04 13,105 1,768,258 Cisco Systems Inc CSCO 17275R102 1.03 32,830 1,739,990 UnitedHealth Group Inc UNH 91324P102 1.00 4,215 1,687,855 Comcast Corp Class A CMCSA 20030N101 0.94 28,021 1,597,757 AT&T Inc T 00206R102 0.91 53,587 1,542,234 Oracle Corp ORCL 68389X105 0.83 18,031 1,403,533 Deere & Co DE 244199105 0.76 3,635 1,282,101 Accenture PLC Class A ACN G1151C101 0.74 4,237 1,249,025 Johnson Controls International PLC JCI G51502105 0.74 18,185 1,248,037 Visa Inc Class A V 92826C839 0.71 5,152 1,204,641 Texas Instruments Inc TXN 882508104 0.70 6,128 1,178,414 Costco Wholesale Corp COST 22160K105 0.67 2,850 1,127,660 Bank of America Corp BAC 060505104 0.64 26,192 1,079,896 Broadcom Inc AVGO 11135F101 0.63 2,223 1,060,015 Abbott Laboratories ABT 002824100 0.57 8,348 967,784 Target Corp TGT 87612E106 0.56 3,949 954,631 Honeywell International Inc HON 438516106 0.56 4,324 948,469 Goldman Sachs Group Inc GS 38141G104 0.53 2,374 901,004
    [Show full text]
  • ANSYS Contact Technology Guide
    ANSYS Contact Technology Guide ANSYS Release 9.0 002114 November 2004 ANSYS, Inc. is a UL registered ISO 9001: 2000 Company. ANSYS Contact Technology Guide ANSYS Release 9.0 ANSYS, Inc. Southpointe 275 Technology Drive Canonsburg, PA 15317 [email protected] http://www.ansys.com (T) 724-746-3304 (F) 724-514-9494 Copyright and Trademark Information Copyright © 2004 SAS IP, Inc. All rights reserved. Unauthorized use, distribution or duplication is prohibited. ANSYS, DesignSpace, CFX, DesignModeler, DesignXplorer, ANSYS Workbench environment, AI*Environment, CADOE and any and all ANSYS, Inc. product names referenced on any media, manual or the like, are registered trademarks or trademarks of subsidiaries of ANSYS, Inc. located in the United States or other countries. ICEM CFD is a trademark licensed by ANSYS, Inc. All other trademarks and registered trademarks are property of their respective owners. ANSYS, Inc. is a UL registered ISO 9001: 2000 Company. ANSYS Inc. products may contain U.S. Patent No. 6,055,541. Microsoft, Windows, Windows 2000 and Windows XP are registered trademarks of Microsoft Corporation. Inventor and Mechanical Desktop are registered trademarks of Autodesk, Inc. SolidWorks is a registered trademark of SolidWorks Corporation. Pro/ENGINEER is a registered trademark of Parametric Technology Corporation. Unigraphics, Solid Edge and Parasolid are registered trademarks of Electronic Data Systems Corporation (EDS). ACIS and ACIS Geometric Modeler are registered trademarks of Spatial Technology, Inc. FLEXlm License Manager is a trademark of Macrovision Corporation. This ANSYS, Inc. software product and program documentation is ANSYS Confidential Information and are furnished by ANSYS, Inc. under an ANSYS software license agreement that contains provisions concerning non-disclosure, copying, length and nature of use, warranties, disclaimers and remedies, and other provisions.
    [Show full text]
  • Inozyme Pharma Expands Medical Leadership Team
    Inozyme Pharma Expands Medical Leadership Team Strengthens Inozyme’s Ability to Advance Lead Candidate, INZ-701, into Clinical Trials Boston, Mass., Nov. 14, 2019 – Inozyme Pharma Inc., a biotechnology company developing novel medicines to treat rare and life-threatening mineralization disorders, today announced the addition of three industry veterans to its leadership team: • Pedro Huertas M.D., Ph.D., as Chief Medical Officer, • Gus Khursigara Ph.D., as Vice President of Medical Affairs and Clinical Operations, and • Catherine Nester, as Vice President of Physician and Patient Strategies. The executives will be instrumental in advancing Inozyme’s lead drug candidate, INZ-701, into clinical trials in 2020 for the treatment of patients with ENPP1 deficiency. INZ-701 is the first therapy that addresses the pathology of ENPP1 deficiency, including diseases such as generalized arterial calcification of infancy (GACI) type 1 and autosomal recessive hypophosphatemic rickets type 2 (ARHR2), both of which are rare and life-threatening manifestations of this enzyme deficiency. Inozyme Pharma received orphan drug designation for INZ-701 in the US and EU in 2018. “We are pleased and excited to welcome Pedro, Gus and Catherine to the Inozyme team,” said Axel Bolte, co-founder and chief executive officer of Inozyme. “Their expertise in orphan drug development – spanning medical affairs, regulatory affairs and clinical development – will strengthen and accelerate our ability to bring potentially life-saving medicines to people who urgently need effective treatments.” Dr. Huertas, a veteran of the pharmaceutical industry, has extensive experience in research and development and medical and regulatory affairs, especially regarding rare disorders and enzyme replacement therapies.
    [Show full text]